Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG-BM1 in Ischemic Stroke
NCT07896941Phase 2Recruiting
- Sponsor
- Guangzhou Saijun Biotechnology Co., Ltd.
- Start
- Sep 2024
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of CG-BM1 in ischemic stroke, sponsored by Guangzhou Saijun Biotechnology Co., Ltd.. Started Sep 2024; status: recruiting.
02
Drugs
CG-BM1
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07896941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07896941.